SCHEMBL30540583

SCHEMBL30540583

COC(=O)c1cc(CN2CCC[C@H](C)C2)c2c(n1)c(F)cn2COCC[Si](C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM2 Q14416 2/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ POLB P06746 3/20 0.34
▸ GAA P10253 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ KLKB1 P03952 1/20 0.33
▸ KDM4E B2RXH2 4/20 0.33
▸ GLA P06280 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ METTL3 Q86U44 1/20 0.32
▸ L3MBTL1 Q9Y468 2/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32
▸ SIRT2 Q8IXJ6 1/20 0.32
▸ MAPT P10636 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31115342 1.00 GRM2 (0.35) GRM2ALDH1A1POLBGAAKMT2A
SCHEMBL31115338 0.92 KDM4E (0.36) GRM2ALDH1A1POLBGAAKMT2A
SCHEMBL30540610 0.92 KDM4E (0.36) GRM2ALDH1A1POLBGAAKMT2A
SCHEMBL30540580 0.92 KLKB1 (0.37) ALDH1A1POLBGAAKMT2AKLKB1
SCHEMBL31115364 0.91 KLKB1 (0.33) GRM2ALDH1A1POLBGAAKMT2A
SCHEMBL30540464 0.91 KLKB1 (0.33) GRM2ALDH1A1POLBGAAKMT2A
SCHEMBL30577554 0.88 GRM2 (0.33) GRM2ALDH1A1POLBGAAKMT2A
SCHEMBL30540453 0.85 KLKB1 (0.39) ALDH1A1POLBGAAKMT2AKLKB1
SCHEMBL30540617 0.84 TERT (0.35) ALDH1A1POLBGAAKMT2AKLKB1
SCHEMBL30577606 0.82 KLKB1 (0.39) GRM2GAAKMT2AKLKB1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-05-22 — — US disclosed
EP-4476219-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BeiGene, Ltd. (KY) 2024-12-18 — — EP disclosed
CN-118696043-A Heterocyclic compounds, compositions thereof and methods of treatment therewith 百济神州有限公司 2024-09-24 — — CN disclosed
WO-2023151641-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 — — WO disclosed
WO-2023151636-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH NFATC1, GZMB, IFNG GRM2 2591/4885ALDH1A1 1242/4885POLB 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback